{"id":4609,"date":"2025-03-31T18:12:14","date_gmt":"2025-03-31T18:12:14","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/oxprenolol-hydrochloride-txt\/"},"modified":"2025-03-31T18:12:14","modified_gmt":"2025-03-31T18:12:14","slug":"oxprenolol-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/oxprenolol-hydrochloride-txt\/","title":{"rendered":"oxprenolol hydrochloride.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nBeta-1 adrenoceptor blocker:Hypertension Angina Arrhythmias Anxiety

DOSE IN NORMAL RENAL FUNCTION <\/H3>Hypertension, angina: 80\u2013160 mg daily in 2\u20133 divided doses; maximum 320 mg dailyArrhythmias: 40\u2013240 mg daily in 2\u20133 divided dosesAnxiety: 40\u201380 mg daily in 1\u20132 divided doses

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :301.8<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :70\u201380 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <3<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.2<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1\u20132\/unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely dialysability. Dose as in normal renal function.<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely dialysability. Dose as in normal renal function.
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: NSAIDs antagonise hypotensive effect\n
  • Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone\n
  • Antidepressants: enhanced hypotensive effect with MAOIsAntihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin; increased risk of withdrawal hypertension with clonidine; increased risk of bradycardia and AV block with diltiazem; severe hypotension and heart failure occasionally with nifedipine; asystole, severe hypotension and heart failure with verapamil\n
  • Antimalarials: increased risk of bradycardia with mefloquine\n
  • Antipsychotics: enhanced hypotensive effect with phenothiazines\n
  • Diuretics: enhanced hypotensive effect\n
  • Moxisylyte: possibly severe postural hypotensionSevere hypertension with adrenaline and noradrenaline (especially with non-selective beta-blockers) and possibly with dopamineTropisetron: increased risk of ventricular arrhythmias \u2013 use with caution

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Use with caution in patients with chronic obstructive airways disease, asthma or diabetesRhabdomyolysis with myoglobinuria has been reported in severe overdosage with oxprenolol
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Beta-1 adrenoceptor blocker:Hypertension Angina Arrhythmias Anxiety DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4609","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4609"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4609\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}